Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. reports company developments for a commercial-stage medical technology and healthcare business centered on neurohealth therapies. Its recurring updates cover the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation platform cleared by the U.S. Food and Drug Administration for adults with major depressive disorder, adjunctive use in obsessive-compulsive disorder, anxious depression symptoms in adults with MDD, and first-line adjunctive treatment of MDD in adolescent patients aged 15-21.
News about STIM also covers operating results, U.S. and international system revenue, clinic services added through the completed Greenbrook acquisition, SPRAVATO-related clinic activity, executive and board changes, inducement equity awards, shareholder engagement, and cost-structure actions.
Neuronetics (NASDAQ: STIM) has appointed Megan Rosengarten to its Board of Directors, expanding the board to eight members. Rosengarten brings over two decades of experience in medical technology, currently serving as President of Surgical Robotics at Medtronic. She previously held roles at Hologic, Covidien, and Johnson & Johnson. Her expertise in product development and marketing is expected to enhance Neuronetics' growth strategy for its NeuroStar Advanced Therapy for Mental Health, which is FDA-cleared for treating major depressive disorder. The company aims to increase awareness and adoption of this innovative therapy.
Neuronetics, a medical technology company, reported a 46% revenue increase to $14.2 million for Q2 2021, driven by a 65% rise in U.S. treatment session revenue. The company highlighted 83% response and 62% remission rates from its NeuroStar Outcomes Registry. While gross margin improved to 80.6%, operating expenses rose to $18 million. A net loss of $(7.5) million was reported, slightly better than the previous year's $(7.8) million. For full-year 2021, revenue is projected between $59 million and $63 million, with Q3 expectations between $15 million and $16 million.
Neuronetics, a commercial-stage medical technology company focused on improving the quality of life for psychiatric disorder patients, announced its participation in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021. CEO Keith Sullivan and CFO Steve Furlong will present at 9:30 am ET. The presentation will be available via live audio webcast on the company’s investor relations page, with a replay accessible for 90 days. Neuronetics’ flagship product, NeuroStar, is a FDA-cleared therapy for major depressive disorder.
Neuronetics, based in Malvern, PA, announced it will release its second quarter financial and operational results on August 3, 2021, before the market opens. A conference call will follow at 8:30 a.m. ET to discuss the results. Investors can listen via a webcast on Neuronetics' investor relations site or by dialing in using a provided telephone number and confirmation code. The company specializes in medical technology aimed at improving the quality of life for patients with psychiatric disorders, notably through its FDA-cleared NeuroStar® Advanced Therapy System.
Neuronetics has launched a redesigned My NeuroStar Resource Center to enhance marketing and educational support for NeuroStar® providers. This digital hub offers over 25 customizable templates and resources to boost treatment awareness for the NeuroStar Advanced Therapy for Mental Health, a non-invasive treatment for depression. With 17.3 million Americans suffering from depression, the resource center aims to help practices effectively reach more patients. Enhancements include improved user experience and new training materials, aligning with the company’s goal to support growth in the TMS market.
Neuronetics (NASDAQ: STIM) announced its inclusion in the Russell 2000 Index effective June 28, 2021, following the annual Russell indexes reconstitution. This recognition is based on the company's market capitalization as of May 7. The Russell index membership enhances Neuronetics' visibility among investors and validates its efforts to create shareholder value through its NeuroStar Advanced Therapy System, aimed at improving mental health outcomes. Approximately $10.6 trillion in assets are benchmarked against Russell indexes, making this a significant milestone for the company.
Neuronetics, a leader in transcranial magnetic stimulation, will showcase real-world clinical data on NeuroStar Advanced Therapy for Mental Health at the Clinical TMS Society Annual Meeting in West Palm Beach, Florida, from June 10-12, 2021. Highlights include presentations on clinical outcomes from the NeuroStar Outcomes Registry, covering efficacy comparisons and treatment protocols. Neuronetics, as a Platinum Sponsor, aims to enhance awareness of TMS's benefits for major depressive disorder. With over 4 million treatment sessions delivered, the company continues to influence mental health treatment.
Neuronetics, a medical technology company listed on NASDAQ under the symbol STIM, will present at The JMP Securities Life Sciences Conference on June 17, 2021, at 10:00 AM ET. CEO Keith Sullivan and CFO Steve Furlong will lead the discussion. A live audio webcast will be available on the company's investor relations page, with an archive accessible for 90 days post-event. Neuronetics focuses on developing products like the NeuroStar® Advanced Therapy System, a TMS treatment approved by the FDA for major depressive disorder.
Neuronetics has appointed Todd Cushman as Vice President of Business Development, effective immediately. This strategic move aims to enhance the company's international strategy and commercial operations, particularly for its NeuroStar Advanced Therapy for treating Major Depressive Disorder. Cushman brings over 35 years of experience, having previously held leadership roles at Bioness, Medtronic, and Acumed. His expertise is expected to drive market innovation in mental health treatment.
Neuronetics, a medical technology company, announced participation at the William Blair 41st Annual Growth Stock Conference on June 3, 2021, at 9:40 AM ET. CEO Keith Sullivan and CFO Steve Furlong will present details about the company’s innovative products designed to enhance the lives of patients with psychiatric disorders. A live audio webcast will be available on the company’s investor relations page, with a replay accessible for 90 days. Neuronetics is known for its NeuroStar® Advanced Therapy System, FDA-cleared for treating major depressive disorder.